EGFR and non-small cell lung carcinoma: One report showed that the combination of BGT226, a novel PI3K/ mammalian target of rapamycin (mTOR) dual inhibitor, and gefitinib, one of epidermal growth factor receptor (EGF-R) tyrosine kinase inhibitors (TKIs), had synergistically inhibitory effects in growth of NSCLC cells through inhibition of PI3K/Akt/mTOR signaling pathways [18].